Next Article in Journal
Reimbursement of Licensed Cell and Gene Therapies Across the Major European Healthcare Markets
Previous Article in Journal
Market Access Pathways for Cell Therapies in France
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 3
Issue 1
10.3402/jmahp.v3.29229
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cost Savings of Anti-TNF Therapy Using a Test-Based Strategy versus an Empirical Dose Escalation in Crohn's Disease Patients Who Lose Response to Infliximab

by
Xavier Roblin
1,
Alain Attar
2,
Michel Lamure
3,*,
Bernard Savarieau
4,
Pierre Brunel
5,
Gérard Duru
3 and
Laurent Peyrin-Biroulet
6
1
Department of Gastroenterology, University Hospital of Saint Etienne, Saint-Etienne, France
2
Department of Gastroenterology, IBD, Nutritional Support, Hôpital Beaujon, Clichy, France
3
Faculté d’Odontologie, Université Claude Bernard Lyon 1, EA 4129, Rue Guillaume Paradin, FR-69372 Lyon Cedex 08, France
4
Nukleus, Paris, France
5
Pharmacy Department, University Hospital of Saint Etienne, Saint-Etienne, France
6
Inserm U954 and Department of Gastroenterology, Université de Lorraine, Nancy, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2015, 3(1), 29229; https://doi.org/10.3402/jmahp.v3.29229
Submission received: 22 July 2015 / Revised: 4 September 2015 / Accepted: 23 September 2015 / Published: 30 October 2015

Abstract

Background: The use of pharmacokinetics is associated with cost savings in anti-tumor necrosis factor (anti-TNF) therapy, but the long-term cost savings in a large cohort of Crohn's disease (CD) patients are unknown. Aim: The goal of this study was to compare the cost of anti-TNF therapy in two cohorts of CD patients losing response to infliximab, one using a test-based strategy and one an empirical dose escalation. Methods: We used a selected mathematical model to describe the trajectories of CD patients based on a discrete event system. This design allowed us to track over a given period a double cohort of patients who moved randomly and asynchronously from one state to another, while keeping all the information on their entire trajectory. Both cohorts were modeled using state diagram parameters where transition probabilities from one state to another are derived from literature data. Costs were estimated based on the French health care system. Results: Cost savings among the 10,000 CD patients using a test-based strategy were €131,300,293 at 5 years. At 5 years the mean cost saving was €13,130 per patient. The direct cost of the test had no impact on the results until the cost per test reached €2,000. Conclusions: A test-based strategy leads to major cost savings related to anti-TNF therapy in CD.
Keywords: infliximab; pharmacokinetics; adalimumab; Crohn's disease; cost saving infliximab; pharmacokinetics; adalimumab; Crohn's disease; cost saving

Share and Cite

MDPI and ACS Style

Roblin, X.; Attar, A.; Lamure, M.; Savarieau, B.; Brunel, P.; Duru, G.; Peyrin-Biroulet, L. Cost Savings of Anti-TNF Therapy Using a Test-Based Strategy versus an Empirical Dose Escalation in Crohn's Disease Patients Who Lose Response to Infliximab. J. Mark. Access Health Policy 2015, 3, 29229. https://doi.org/10.3402/jmahp.v3.29229

AMA Style

Roblin X, Attar A, Lamure M, Savarieau B, Brunel P, Duru G, Peyrin-Biroulet L. Cost Savings of Anti-TNF Therapy Using a Test-Based Strategy versus an Empirical Dose Escalation in Crohn's Disease Patients Who Lose Response to Infliximab. Journal of Market Access & Health Policy. 2015; 3(1):29229. https://doi.org/10.3402/jmahp.v3.29229

Chicago/Turabian Style

Roblin, Xavier, Alain Attar, Michel Lamure, Bernard Savarieau, Pierre Brunel, Gérard Duru, and Laurent Peyrin-Biroulet. 2015. "Cost Savings of Anti-TNF Therapy Using a Test-Based Strategy versus an Empirical Dose Escalation in Crohn's Disease Patients Who Lose Response to Infliximab" Journal of Market Access & Health Policy 3, no. 1: 29229. https://doi.org/10.3402/jmahp.v3.29229

APA Style

Roblin, X., Attar, A., Lamure, M., Savarieau, B., Brunel, P., Duru, G., & Peyrin-Biroulet, L. (2015). Cost Savings of Anti-TNF Therapy Using a Test-Based Strategy versus an Empirical Dose Escalation in Crohn's Disease Patients Who Lose Response to Infliximab. Journal of Market Access & Health Policy, 3(1), 29229. https://doi.org/10.3402/jmahp.v3.29229

Article Metrics

Back to TopTop